Navigation Links
Resverlogix Presents ASSERT Human Clinical Trial Data at the American Heart Association Late Breaker Session
Date:11/17/2010

hat the three key biomarkers in the reverse cholesterol transport (RCT) process showed dose dependant and consistent improvement. The trial showed dose dependent increases in ApoA-l, statistically significant increases in HDL cholesterol including alpha1 particles or functional HDL, and highly statistically significant increases in large HDL particles. RCT is a pathway by which accumulated cholesterol is transported from the arterial wall to the liver for excretion, thus reducing and/or preventing atherosclerosis.

In the high dose, ApoA-I achieved a 5.6% increase with a statistical value of p=0.06. The overall ApoA-I biomarker showed a dose trending statistical significance of p=0.035. Data presented also showed that the ApoA-I and other HDL particles continued to be increasing at the end of the 12 week study. Both the 8.3% HDL cholesterol increase and the 21.1% large particle HDL increase were highly statistically significant, p<0.01 and p<0.001 respectively. These pronounced HDL related increases via ApoA-I production are important as they take place later in the RCT chain of events and strongly indicate plaque regression potential.

"These are very encouraging early findings which suggest the drug (RVX-208) is working in the established patient population that it was designed for, being patients with advanced coronary disease,"  said Dr. Stephen Nicholls, MBBS, PhD, Medical Director of Intravascular Ultrasound and Angiography Core Laboratories at Cleveland Clinic and Clinical Director of the Cleveland Clinic Center for Cardiovascular Diagnostics and Prevention.

Donald McCaffrey, President and Chief Executive Officer of Resverlogix commented, "The study largely replicates findings previously seen in our earlier 28 day trial, more importantly these findings are now being shown in patients with coronary artery disease on optimal  standard of care. The positive changes seen in this trial represent advancem
'/>"/>

SOURCE Resverlogix Corp.
Copyright©2010 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Resverlogix Notice of Conference Call & Webcast to Discuss ASSERT Clinical Trial Data
2. Resverlogix Appoints Kenneth J. Zuerblis to Board of Directors
3. Resverlogixs Phase 2 ASSURE Trial Amended
4. Resverlogix Scientific Data Presented at EAS Congress
5. Resverlogix Completes Dosing for ASSERT Trial
6. Resverlogix Notice of Conference Call & Webcast for Year End Update
7. Resverlogix Activates First Site for ASSURE 1 Clinical Trial
8. Resverlogix Completes Patient Recruitment for ASSERT Trial
9. Arthur J. Higgins, CEO of Bayer HealthCare, Appointed to Resverlogix Board of Directors
10. Resverlogix Presenting at Biotech Showcase
11. Resverlogix Commences Phase 2 Atherosclerosis Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/19/2013)... 2013 The JM Internet Group (web: ... has proudly announced that the company's YouTube channel on ... 175,000 views on YouTube. The company uses YouTube as ... tips and training for small businesses with much success. ... YouTube tips helpful for their SEO strategies", explained Jason ...
(Date:5/17/2013)... (PRWEB) May 17, 2013 Dr. Sparano ... and Women’s Health at the Albert Einstein College of ... at the Montefiore Medical Center. He is also ... Center and leads the Einstein Breast Cancer Working Group, ... translational breast cancer research. He also serves as Vice ...
(Date:5/17/2013)... transplant recipient,s immune system identifies the transplanted organ as ... that T cells, the immune cells that mediate rejection, ... in order to migrate to the transplanted organ. In ... , Fadi Lakkis and colleagues at the University of ... T cells is not required for migration. Instead, these ...
(Date:5/17/2013)... 17, 2013 - Elsevier, a world-leading provider of scientific, ... the publication of a recent study in ... blastocysts showing that those with an abnormal chromosomal composition ... have developed to blastocysts, thereby classifying the risk of ... the same group has undertaken a retrospective study, using ...
Breaking Biology Technology:YouTube Channel on SEO Tips Surpasses 175,000 Views, Announces JM Internet Group 2Joseph A. Sparano, MD, Named Vice Chair of ECOG-ACRIN Cancer Research Group 2Joseph A. Sparano, MD, Named Vice Chair of ECOG-ACRIN Cancer Research Group 3Breakthrough for IVF? 2Breakthrough for IVF? 3
... lead sponsorship of the International Genetically Engineered ... by the Massachusetts Institute of Technology (MIT). ... undergraduate teams representing more than 1,000 students ... America, and the U.S. to design and ...
... preliminary data,from a Phase II/III clinical trial of ... heart failure will be presented next,week at a ... Sessions 2008 in New Orleans., John R. ... Francisco, will present the data from the multicenter, ...
... Nov. 3 Verenium Corporation,(Nasdaq: VRNM ), ... and high-performance specialty enzymes, announced today that it,will ... November 10,2008 after market close. In conjunction with ... with live webcast on Monday, November 10 at ...
Cached Biology Technology: The MathWorks Sponsors iGEM Competition for Synthetic Biology at MIT : MATLAB and SimBiology Help Accelerate Design of Synthetic Biological Systems 2 The MathWorks Sponsors iGEM Competition for Synthetic Biology at MIT : MATLAB and SimBiology Help Accelerate Design of Synthetic Biological Systems 3Top-Line Preliminary Data From Phase II/III Study of Corthera's Relaxin in Acute Heart Failure to be Presented in Satellite Symposium at AHA Scientific Sessions 2008 2Verenium Corporation to Announce Third Quarter 2008 Financial Results 2Verenium Corporation to Announce Third Quarter 2008 Financial Results 3
(Date:5/17/2013)... Bethesda, MD The Federation of American Societies for ... of National Institutes of Health (NIH) funding trends highlighting ... to support critical research. The FASEB analysis follows a ... Francis Collins, MD, PhD, who testified that the $1.6 ... to sequestration is "having a substantial impact on the ...
(Date:5/16/2013)... FASEB MARC (Maximizing Access to Research Careers) ... The Society for Developmental Biology (SDB) 72nd Annual ... These awards are meant to promote the entry ... into the mainstream of the basic science community ... at the SDB 2013 Annual Meeting. , Awards ...
(Date:5/16/2013)... MA -- Injectable nanoparticles developed at MIT may ... 1 diabetes to constantly monitor their blood-sugar levels ... were designed to sense glucose levels in the ... of insulin, thereby replacing the function of pancreatic ... Type 1 diabetes. Ultimately, this type of system ...
Breaking Biology News(10 mins):Nanotechnology could help fight diabetes 2Nanotechnology could help fight diabetes 3
... it tough for Foghat to get much airplay these days, ... in The American Naturalist . Behavioral ecologist Elizabeth ... white-crowned sparrows change over time in response to changing habitats. ... evolution of mating signals in birds. Derryberry says she ...
... University have discovered a previously unknown pathway in plant ... assistant professor in genetics, development and cell biology, examined ... hormone controls the growth of cells. , The brassinosteroids ... plant grows, says Yin. , "Previously, we knew that ...
... for Optimizing CHO Performance,” to feature new supplement ... BIO 2009 International Convention in Atlanta, GA.  , ... b3c newswire / – InVitria’s Director of Cell ... enhancing features of ZAP-CHO, a new media component ...
Cached Biology News:Bird songs change with environment 2ISU researcher identifies genetic pathway responsible for much of plant growth 2InVitria to Unveil Powerful Cell Culture Media Component ZAP-CHO 2